Compare BLZE & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | MDWD |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.4M | 224.6M |
| IPO Year | 2021 | 2014 |
| Metric | BLZE | MDWD |
|---|---|---|
| Price | $4.12 | $17.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $9.50 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 634.6K | 135.7K |
| Earning Date | 02-23-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $141,859,000.00 | $20,932,000.00 |
| Revenue This Year | $16.40 | $6.97 |
| Revenue Next Year | $10.46 | $23.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.73 | 6.15 |
| 52 Week Low | $3.94 | $14.14 |
| 52 Week High | $10.86 | $22.51 |
| Indicator | BLZE | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 30.00 | 46.81 |
| Support Level | $3.95 | $17.10 |
| Resistance Level | $4.75 | $18.48 |
| Average True Range (ATR) | 0.22 | 0.72 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 12.35 | 52.43 |
Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.